- Home
- VTYX vs MIST Comparison
VTYX vs MIST Comparison
Compare VTYX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- MIST
- Stock Information
- Founded
- VTYX 2018
- MIST 2003
- Country
- VTYX United States
- MIST Canada
- Employees
- VTYX N/A
- MIST N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- VTYX Health Care
- MIST Health Care
- Exchange
- VTYX Nasdaq
- MIST Nasdaq
- Market Cap
- VTYX 154.9M
- MIST 145.3M
- IPO Year
- VTYX 2021
- MIST N/A
- Fundamental
- Price
- VTYX $2.30
- MIST $1.96
- Analyst Decision
- VTYX Buy
- MIST Strong Buy
- Analyst Count
- VTYX 2
- MIST 3
- Target Price
- VTYX $9.00
- MIST $6.33
- AVG Volume (30 Days)
- VTYX 441.6K
- MIST 1.2M
- Earning Date
- VTYX 11-06-2025
- MIST 11-11-2025
- Dividend Yield
- VTYX N/A
- MIST N/A
- EPS Growth
- VTYX N/A
- MIST N/A
- EPS
- VTYX N/A
- MIST N/A
- Revenue
- VTYX N/A
- MIST N/A
- Revenue This Year
- VTYX N/A
- MIST N/A
- Revenue Next Year
- VTYX N/A
- MIST N/A
- P/E Ratio
- VTYX N/A
- MIST N/A
- Revenue Growth
- VTYX N/A
- MIST N/A
- 52 Week Low
- VTYX $0.78
- MIST $0.63
- 52 Week High
- VTYX $3.39
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- VTYX 39.52
- MIST 66.84
- Support Level
- VTYX $2.31
- MIST $1.75
- Resistance Level
- VTYX $2.54
- MIST $1.83
- Average True Range (ATR)
- VTYX 0.14
- MIST 0.09
- MACD
- VTYX -0.02
- MIST 0.01
- Stochastic Oscillator
- VTYX 0.00
- MIST 90.91
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).